Montanova Capital LLC Has $5.98 Million Holdings in Boston Scientific Corporation $BSX

Montanova Capital LLC grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 13.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 140,083 shares of the medical equipment provider’s stock after buying an additional 16,142 shares during the quarter. Montanova Capital LLC’s holdings in Boston Scientific were worth $5,979,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of BSX. CYBER HORNET ETFs LLC grew its position in Boston Scientific by 3.4% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock worth $391,000 after acquiring an additional 132 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management raised its position in Boston Scientific by 4.7% in the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock valued at $294,000 after purchasing an additional 139 shares during the last quarter. Northwestern Mutual Investment Management Company LLC boosted its stake in Boston Scientific by 0.3% in the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock worth $4,516,000 after purchasing an additional 140 shares in the last quarter. Kingsview Wealth Management LLC grew its holdings in shares of Boston Scientific by 2.4% during the fourth quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock worth $578,000 after purchasing an additional 142 shares during the last quarter. Finally, Fairfield Financial Advisors LTD grew its holdings in shares of Boston Scientific by 2.9% during the fourth quarter. Fairfield Financial Advisors LTD now owns 5,366 shares of the medical equipment provider’s stock worth $512,000 after purchasing an additional 150 shares during the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 3.2%

Shares of BSX opened at $48.35 on Tuesday. The stock’s fifty day simple moving average is $46.65 and its 200-day simple moving average is $56.35. The firm has a market capitalization of $70.07 billion, a PE ratio of 19.57, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company’s revenue was up 7.5% on a year-over-year basis. During the same period last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current year.

Boston Scientific declared that its board has initiated a stock buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger purchased 2,100 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The stock was acquired at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This represents a 13.94% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig acquired 5,000 shares of the business’s stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the acquisition, the director directly owned 30,359 shares of the company’s stock, valued at $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 194,522 shares of company stock worth $9,385,210 in the last quarter. 0.34% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BSX. BTIG Research cut their price target on Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, July 29th. The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a report on Thursday, May 28th. Needham & Company LLC lowered their price objective on shares of Boston Scientific from $77.00 to $57.00 and set a “buy” rating for the company in a research report on Wednesday, July 8th. Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. Finally, Mizuho reduced their target price on shares of Boston Scientific from $90.00 to $70.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 15th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.